Universal Health Services UHS
Healthcare · Medical - Care Facilities · Synthos Deep Dive · 2026-07-03
The Overview
UHS runs hospitals — about 29 acute-care hospitals and hundreds of mental-health (behavioral) facilities across the US and the UK. When you go to the ER, have surgery, or get treated for addiction or a mental-health crisis, a company like this owns the building, employs the staff, and bills your insurance or Medicaid.
The stock is cheap — you're paying only about $6.70 for every $1 the company earns per year, less than half what the average big US company costs. It got cheap because the price fell hard (down about a third from its high) on worries about government healthcare funding. Meanwhile the business itself is doing fine and earnings are actually going up. So our verdict is Buy — Tactical: a reasonable value buy for the patient, but a bet on the price recovering rather than on explosive growth.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly safe on the numbers). Cheap and not heavily indebted, so there's a floor — but the stock swings with the market and has already fallen a lot, which shows how touchy it is to bad news.
- Growth Quality 6/10 (solid, unspectacular). It grows slowly (~5% a year in sales) but reliably, and it buys back a lot of its own stock, which quietly boosts earnings per share.
- Exponential Potential 3/10 (low). This is a mature business. It won't double overnight from growth; the upside is the price catching back up to what the earnings are worth.
The one big worry: most of UHS's money ultimately flows from government insurance (Medicaid) and government-subsidized coverage. If Washington or the states cut those programs, UHS's volumes and payment rates get squeezed — that's exactly the fear that made the stock cheap.
Putting a number on it: our fair-value estimate is $245 against a current price of $171.66 — real upside if our numbers are right.
Our summary metrics
Cheap (6.7× fwd, EV/EBITDA 5.3×) & low leverage (net-debt/EBITDA 1.8×) — offset by beta 1.08, −35% drawdown, Medicaid/policy cyclicality.
Only ~5% fwd revenue & ~7-8% EPS CAGR, but margins & ROE (21%) rising and buybacks compound per-share.
Mature hospital operator — decelerating top line, huge but saturated TAM; no exponential leg. Value, not growth.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature hospital operator — decelerating top line, huge but saturated TAM; no exponential leg. Value, not growth.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $216 (high $310 / low $165; 18 Buy · 23 Hold · 2 Sell — "Hold") — context, not our anchor |
| Valuation | 6.7× trailing EPS · 6.7× FY26E · 6.3× FY27E · 5.3× FY29E · EV/S 0.84× · EV/EBITDA 5.3× |
| Technicals | Downtrend — $158, −35% off 52-wk high, below the 200-DMA ($196), RSI 72 (bouncing hard), −16% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices in the Synthos KB; this is a quant/fundamentals call, transparently |
| Position sizing | Value/tactical satellite, ~1–3%, on the mean-reversion + buyback thesis |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for UHS — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $171.66, 7% above the 50-day average ($161), 8% below the 200-day average ($187) — a mixed trend. 30% below the 52-week high of $244, 22% above the 52-week low of $141.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $171.66 is currently inside the band (band $167–$178).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 54.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.59, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = UHS · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Universal Health Services (NYSE: UHS), founded 1978 and headquartered in King of Prussia, PA, is one of the largest US hospital operators, run through two reporting segments. As of the latest earnings release it operates roughly 29 inpatient acute-care hospitals, 346 inpatient behavioral-health facilities, and 168 outpatient/ambulatory access points, plus an insurance operation, with ~101,500 employees. CEO is Marc D. Miller; founder Alan B. Miller remains Executive Chairman and controls the company through super-voting Class A stock. Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
- By segment: Acute Care Hospital Services $9.93B (57%) · Behavioral Health Services $7.43B (43%). The two legs are roughly balanced — acute care is higher-revenue but lower-margin and more capital-intensive; behavioral health is the higher-margin, differentiated franchise.
- By geography: predominantly United States, with a UK behavioral-health operation (~$0.76B of behavioral revenue was non-US in FY2023, the last year FMP breaks it out). This is a domestically concentrated business — a US-policy exposure, not a global one.
The strategic story is steady: same-facility volume plus pricing growth, disciplined new-hospital builds in growing Sun Belt markets, a large buyback, and a pending bolt-on acquisition of Talkspace, Inc. (virtual behavioral health) to extend the behavioral franchise online.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of UHS in the Synthos knowledge base. total_claims = 0; zero net-bullish voices, zero cautionary voices, zero traceable claim_ids. We will not manufacture a panel that does not exist — honesty comes first.
Accordingly, this verdict is fundamentals- and quant-driven, built entirely from the reported financials, live analyst estimates, valuation, and technicals in the sections that follow. Where we cite a number it comes from the FMP data file or UHS's own SEC filing, not from a distilled expert claim. Readers who weight this note should treat it as a quantitative/valuation call with no independent expert corroboration — a lower bar than our conviction-track names (e.g. names with a 10-plus-voice panel). The Street's own read is a lukewarm "Hold" (18 Buy / 23 Hold / 2 Sell), which we take as context, not endorsement.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Below-average risk | Cheap (6.7× fwd EPS, 5.3× EV/EBITDA) and modestly levered (net-debt/EBITDA 1.8×, interest coverage 13.6×) give a valuation floor; offset by beta 1.08, a −35% drawdown already in the price, and structural Medicaid/policy cyclicality. |
| Growth Quality | 6 · Solid | Only ~5% forward revenue CAGR and ~7–8% EPS CAGR, but margins are widening (EBITDA margin 15.7% TTM, up from ~12% in FY23), ROE is a healthy 21%, ROIC ~12%, and a ~10%/yr buyback compounds per-share results. Quality is fine; growth rate is pedestrian. |
| Exponential Potential | 3 · Low | A mature hospital operator. Top line is decelerating (+9.7% FY25 → ~+4.6% FY27E) and the addressable market, while enormous, is saturated and policy-capped. No exponential leg — the upside is re-rating and buybacks, not a growth explosion. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Medicaid supplemental-payment and ACA-subsidy fears fade; volumes and behavioral pricing stay firm; buyback shrinks the share count fast. FY27E EPS beats to ~$27; the multiple re-rates toward its historical ~12×. | ~$330 (+108%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$25.3; the extreme discount partially closes as the policy overhang clarifies; multiple re-rates to a still-modest ~9.5–10×. | ~$245 (+55%) |
| Bear | Medicaid supplemental-payment cuts and ACA-subsidy expiry bite: volume/mix pressure caps EPS near ~$23 and the market keeps UHS at a distressed ~6.5× as policy risk lingers. | ~$150 (−5%) |
Synthos fair value = the base case, ~$245 (+55%), with the full $150–$330 span as the honest range. Even our bear ($150) is close to today's price — a sign of how much pessimism is already in the stock. Our base sits above the Street's $216 consensus because we give more credit to a valuation-mean-reversion, while our bear respects that the policy overhang is real. This is a tracked call — the Forecaster Scorecard grades it once it matures. Note the wide, asymmetric range: the risk here is a value trap (multiple never recovers), not a fundamental blow-up.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). UHS is neither an exponential nor even a fast compounder — it is a cheap, mature cash-flow business:
- Forward growth: revenue CAGR FY25→FY29E ~4.8% ($17.4B → $21.0B); EPS CAGR ~7–8% ($23.10 → ~$30) — the EPS growth outrunning revenue thanks to margin gains and buybacks, not organic acceleration.
- Acceleration (the 2nd derivative) is negative: revenue growth +9.7% (FY25) → +6.7% (FY26E) → +4.6% (FY27E). The post-COVID labor-cost normalization and pricing recovery that drove the FY24–25 earnings surge are largely behind it; from here UHS is a low-to-mid-single-digit top-line grower.
- Room to run: the US hospital/behavioral-care TAM is enormous in dollar terms, but it is saturated, regulated, and payer-capped — you don't get exponential unit economics from it. At a ~$9.9B cap the stock could plausibly double on re-rating alone, but that is multiple recovery, not a growth multibagger.
- Reinvestment runway: capex ~$1.0B/yr into new hospitals is productive but incremental; the more powerful per-share lever is the buyback (~$968M repurchased in FY25, shrinking the count from ~66.5M to ~61M shares).
Exponential Potential: Low (3/10). Own UHS for value and per-share compounding, explicitly not for exponential growth. This is a re-rating and buyback story — which is why it lands in the value/tactical sleeve, not the growth or degen tier.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $17.36B, +9.7% (FY24 $15.83B, +10.8% on FY23 $14.28B). Steady high-single/low-double-digit top line at scale.
- Quarterly trajectory: Q1'25 $4.10B → Q2 $4.28B → Q3 $4.50B → Q4 $4.49B → Q1'26 $4.50B (+9.6% YoY). Growth is steady, not accelerating.
- Margins (the real story): gross ~71% TTM, EBITDA margin 15.7% TTM (up from ~12.0% in FY23), operating ~11.5%, net ~8.6%. The margin recovery off the FY22–23 labor-cost trough is what drove earnings, and it is largely captured now.
- Earnings: net income $1.489B FY25 (+30% on FY24's $1.142B); diluted EPS $23.10 vs $16.82 — a two-year near-doubling off the FY23 $10.23 trough. Q1'26 EPS $5.65 (+18% YoY).
- Cash flow: operating CF $1.86B FY25, capex ~−$1.02B (new-hospital builds), FCF ~$0.85B; FY24 FCF was a stronger $1.12B (FY25 FCF dipped on a working-capital swing and higher capex). FCF yield ~9% is healthy.
- Balance sheet: total debt ~$5.51B, net debt ~$5.37B, net-debt/EBITDA ~1.8× — moderate and easily serviced (interest coverage 13.6×). Note the April-2026 credit-agreement amendment adding $900M of capacity, partly to fund the Talkspace deal. Goodwill ~$4.0B (25% of assets) is the main balance-sheet soft spot.
6. Valuation — priced in or room?
UHS is genuinely cheap on every earnings-based metric: 6.7× trailing EPS, 6.7× FY26E, 6.3× FY27E, 5.3× FY29E, EV/Sales 0.84×, EV/EBITDA 5.3×, FCF yield ~9%, P/B 1.28×. For context, hospital operators historically trade ~9–13× forward earnings; UHS itself averaged low-double-digits over the past cycle. FMP's own letter rating is "A" (overall score 4/5, strong DCF/ROE/ROA sub-scores; the one weak sub-score is debt-to-equity).
The bear's defense of the low multiple is that it is deserved: hospital earnings lean on Medicaid supplemental-payment programs and ACA marketplace subsidies, both of which face policy cuts — so the market is discounting a possible earnings air-pocket, not mispricing a stable stream. That is a real debate, and it is why this is a tactical value buy rather than a core one.
Reverse read: at 6.3× FY27E, the market is effectively pricing no multiple recovery and some earnings erosion. Any clarity that the policy hit is manageable — or simple continuation of the buyback — should re-rate the stock. Street targets (context): consensus $216, high $310, low $165, median $204 — our $245 base is above consensus because we weight the mean-reversion case, but note even the Street low ($165) sits above today's price. Not a growth buy; a deep-value, re-rating buy.
7. Technicals (from the tech block)
- Trend: down. $158 sits below the 200-DMA ($196) and roughly at the 50-DMA ($157). The 50 below the 200 is a death-cross posture. MACD −1.49 (negative). This is a downtrend trying to base, not an uptrend.
- Location: −35% off the 52-week high ($244), only +12% off the 52-week low ($141) — near the lows, with a −35% max drawdown from peak. A beaten-down name, which is the source of the value.
- Momentum: RSI(14) 72 — technically overbought, reflecting a sharp +5.1% single-day bounce on the print day. Short-term the snap-back is stretched; don't chase the green candle.
- Relative strength (the tell): UHS −16.2% 12-mo vs SPY +20.6% and QQQ +30.3%; −11% 3-mo vs SPY +14%. Persistent, heavy underperformance — the mirror image of a leadership name.
- Read: technicals do not confirm the value thesis yet — price is below its long-term average in a death-cross with an overbought short-term bounce. The disciplined approach is to scale in on weakness / let it base above the 200-DMA, not buy the RSI-72 spike. A reclaim of the $196 200-DMA would be the trend-confirmation signal.
8. Moat & competitive position
UHS's advantages are scale, real estate, and a differentiated behavioral-health franchise — not a wide economic moat. Hospital operating is a capital-intensive, regulated, locally-competitive business with limited pricing power against government payers. The genuine edge is the behavioral-health segment (43% of revenue), where UHS is one of the largest US operators; it is higher-margin, more consolidated, and harder to replicate than commodity acute care. The pending Talkspace acquisition extends that franchise into virtual care. Founder-family control (Class A super-voting stock) gives long-term operating discipline but weakens minority-shareholder governance.
Peer set (market cap): HCA Healthcare $91B (the dominant acute-care comp), Tenet Healthcare $17.5B, DaVita $15.1B, Fresenius Medical Care $12.6B, Encompass Health $10.6B, Ensign Group $9.8B, Acadia Healthcare $2.9B (the closest behavioral-health pure-play), Surgery Partners $2.3B, Select Medical $2.0B, Community Health Systems $0.55B. UHS is mid-cap in the group and trades at a discount to larger, faster HCA — some of which is deserved (HCA has better markets/scale), some of which is the re-rating opportunity.
9. Management, capital allocation & guidance
- Capital allocation: shareholder-friendly and disciplined — ~$968M of buybacks in FY25 (shrinking the count ~8%), a small dividend (~0.5% yield, 3% payout), and ~$1.0B/yr into new-hospital capex. With ~$1.30B of buyback authorization remaining as of Q1'26, the per-share compounding lever is intact. The April-2026 credit-agreement expansion (+$900M capacity) funds the Talkspace deal without stressing the balance sheet.
- Insider activity: the recent Form 4s from Executive Chairman Alan B. Miller (filed 2026-05-29) are J-Other / gift-type transfers at $0 price (estate/trust planning, Class B stock), not open-market discretionary sales — no negative signal to read from them.
- Management's own guidance (the earnings-release track): the latest SEC 8-K earnings release we ingested (Q1'26, filed 2026-04-28) is a real results release — it details 9.6% revenue growth, same-facility acute (+8.2%) and behavioral (+7.3%) revenue, EBITDA net of NCI of $651.7M, the buyback, and the Talkspace-related credit amendment. However, it contains no explicit forward revenue/EPS/EBITDA guidance range (UHS's release is backward-looking results, not a formal outlook). So management's own dated forward guidance was not available in this filing; treat the forward path here as analyst consensus (FMP), labeled as estimates, not company guidance.
10. Catalysts & what to watch
- Next earnings: 2026-07-27 (Q2'26; Street EPS $5.92, revenue ~$4.58B). The key lines: same-facility volume and revenue-per-adjusted-admission in both segments, and any commentary on Medicaid supplemental payments.
- US healthcare policy: the single biggest swing factor — Medicaid supplemental/state-directed-payment program changes and the fate of enhanced ACA marketplace subsidies. Clarity in either direction re-rates the stock.
- Talkspace acquisition: close, price, and integration of the virtual behavioral-health deal — the growth-optionality item.
- Buyback pace: continued aggressive repurchase = per-share EPS tailwind and a signal management sees the stock as cheap.
- Behavioral-health margins & volume: the differentiated, higher-margin leg — watch for any softening.
Thesis tripwires (what would change the call): a confirmed material Medicaid/ACA funding cut that dents FY27 EPS below ~$22; behavioral-segment volume rolling over; the buyback slowing sharply; or price failing to base and breaking the 52-week low ($141) on rising volume (value-trap confirmation).
11. Key risks
- Government-payer policy (structural, the reason it's cheap): heavy reliance on Medicaid supplemental payments and ACA-subsidized coverage; cuts would pressure both volume (uninsured rates rise) and rate/mix. This is the dominant risk.
- Value trap / no re-rating: the discount may simply persist if policy uncertainty lingers — the multiple never recovers even as earnings hold, so the +55% base case never gets paid.
- Cyclicality & labor costs: hospital margins are sensitive to wage inflation and nurse-staffing costs; the FY22–23 margin trough shows how fast it can bite.
- Balance-sheet / goodwill: ~$4.0B goodwill (25% of assets); an impairment or a debt-funded deal misstep would hurt.
- Governance: founder-family Class A super-voting control limits minority-shareholder influence.
- No expert corroboration: zero Synthos KB coverage — this call rests solely on quant/fundamentals, a lower-conviction footing than our multi-voice names.
12. Verdict, position sizing & monitoring
Buy — Tactical. UHS is a genuinely cheap (6.7× earnings, 5.3× EV/EBITDA, ~9% FCF yield), well-managed, buyback-heavy hospital operator whose stock has fallen ~35% on real-but-discountable US healthcare-policy fears while its earnings actually rose (+37% EPS in FY25). The setup is a valuation mean-reversion plus per-share compounding, not a growth story — and it comes with no expert-panel corroboration (0 KB claims), so we rate conviction Low and size it accordingly.
- Sizing: value/tactical satellite, ~1–3% of the book. Because the technicals are in a downtrend with an overbought short-term bounce (RSI 72), scale in on weakness rather than chasing the spike; a reclaim of the $196 200-DMA is the trend-confirmation add point.
- Monitoring: re-underwrite on the tripwires in §10; the July-27 print and any Medicaid/ACA policy headline are the key checkpoints. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $158.33.
- Single biggest risk: US government-payer policy — a Medicaid supplemental-payment or ACA-subsidy cut is the one thing that turns the cheap multiple from an opportunity into a value trap.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of UHS in the Synthos knowledge base, and this note states that plainly. The verdict is quant/fundamentals-driven from the FMP data file and UHS's SEC 8-K. No
claim_ids are cited because none exist; fabricated conviction is structurally impossible (claim-ID reconciliation) and, here, transparently absent. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Management caveat: UHS's Q1'26 earnings release contains results but no formal forward guidance; the forward path shown is consensus, not company guidance.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").